Celgene Phase III Revlimid Data Show Survival Advantage In Multiple Myeloma Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial also showed longest median time to disease progression, 11.3 months, reported in previously treated MM patients in a Phase III study.
You may also be interested in...
Vidaza Key To Celgene’s $2.9 Billion Pharmion Purchase
Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.
Celgene’s Revlimid Approved For Second-Line Multiple Myeloma
Firm will begin shipping 15 mg and 25 mg tablets at the end of the first week of July following sNDA approval announced June 29.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.